Vicarious Surgical to Announce Q4 and Full-Year 2023 Financial Results
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS), a pioneering company specializing in next-generation robotic technology for surgery, has confirmed the release date for its financial results for the fourth quarter and full year of 2023. The announcement is set to be made on March 4, 2024, after the market closes, followed by a conference call at 4:30 p.m. Eastern Time.
Founded in 2014 and headquartered in Waltham, Massachusetts, Vicarious Surgical aims to revolutionize surgical procedures by enhancing efficiency and outcomes while reducing healthcare costs. The company’s innovative approach involves the use of proprietary human-like surgical robots that enable a virtual presence inside the patient, enabling minimally invasive surgery. The leadership team at Vicarious Surgical comprises seasoned professionals from the technology, medical device, and healthcare sectors.
Vicarious Surgical has received notable attention and backing from prominent figures in the technology and investment fields, including Bill Gates, and entities such as Khosla Ventures, Innovation Endeavors, AME Cloud Ventures, Sun Hung Kai & Co. Ltd, and E15 VC.
Investors have keenly monitored Vicarious Surgical’s performance metrics and analyst insights as the company prepares to unveil its financial results. According to InvestingPro data, the company currently boasts a market capitalization of $72.23 million. However, the financial health of Vicarious Surgical has posed challenges, with an adjusted P/E ratio for the last twelve months as of Q3 2023 standing at -1.04, indicating a lack of profitability during this period.
InvestingPro Tips highlight that Vicarious Surgical holds more cash than debt on its balance sheet, potentially providing a cushion for operational needs or strategic initiatives. Furthermore, four analysts have revised their earnings projections upwards for the forthcoming period, indicating potential optimism about the company’s future performance.
Nevertheless, it is important to note that Vicarious Surgical has been depleting cash at a rapid pace and faces weak gross profit margins. The company’s stock price has also exhibited significant volatility, with a 28.77% decline over the past month and an 87.01% drop over the last year according to available data.
Analyst comment
Neutral news.
As an analyst, the market is likely to react cautiously to Vicarious Surgical’s financial results. While the company has received notable backing and potential optimism from analysts, its lack of profitability, weak gross profit margins, and declining stock price could impact investor confidence. The market will closely monitor the company’s cash position and future performance indicators.
